CGEN - Compugen Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6032
+0.1032 (+2.95%)
As of 12:31PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.5000
Open3.5000
Bid3.59 x 3000
Ask3.63 x 800
Day's Range3.5000 - 3.6400
52 Week Range2.0000 - 5.0000
Volume27,874
Avg. Volume155,010
Market Cap206.092M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.42
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET

    HOLON, Israel , Feb. 14, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...

  • PR Newswire29 days ago

    Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

    HOLON, Israel, Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint and the potential of COM701, Compugen's first-in-class inhibitory antibody targeting PVRIG, to serve as an effective cancer immunotherapy. The findings were published in two peer-reviewed papers in Cancer Immunology Research, an American Association for Cancer Research publication. Both papers were co-authored by Compugen's scientists in collaboration with scientists from Johns Hopkins University School of Medicine, headed by Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine, and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, and Chairman of Compugen's Scientific Advisory Board.

  • How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own?
    Simply Wall St.last month

    How Much Of Compugen Ltd. (NASDAQ:CGEN) Do Institutions Own?

    Every investor in Compugen Ltd. (NASDAQ:CGEN) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...

  • PR Newswirelast month

    Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

    HOLON, Israel, Jan. 14, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA. Compugen is a clinical-stage, therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy.

  • GlobeNewswire3 months ago

    New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire3 months ago

    Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy

    HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

  • Compugen (CGEN) Reports Q3 Loss
    Zacks3 months ago

    Compugen (CGEN) Reports Q3 Loss

    Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Compugen: 3Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...

  • PR Newswire3 months ago

    Compugen Reports Third Quarter 2018 Results

    HOLON, Israel , Nov. 7, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...

  • Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?
    Zacks4 months ago

    Compugen Ltd. (CGEN) Sees Hammer Chart Pattern: Time to Buy?

    Compugen has been struggling lately, but the selling pressure may be coming to an end soon.

  • PR Newswire4 months ago

    Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET

    HOLON, Israel , Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...

  • Benzinga4 months ago

    Don't Fixate On Market Woes, Just Make Your Trades

    Beyond my recent losses, October has actually been a strong month for me, although some in the chat are wondering how the recent market-wide selloff is affecting day traders. It was a fairly typical day for me, I was up, then down, then up again. Two of the top stocks to appear on my premarket scanner on Thursday, Spherix Inc. (NASDAQ: SPEX) and Compugen Ltd. (NASDAQ: CGEN), both collapsed on the opening bell.

  • Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
    Zacks4 months ago

    Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

    AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

  • Bristol-Myers Inks Deal and Invests $12 Million in Compugen
    Zacks4 months ago

    Bristol-Myers Inks Deal and Invests $12 Million in Compugen

    Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.

  • Reuters4 months ago

    Bristol-Myers to invest in Compugen, collaborate in clinical trials

    Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumours. The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo. In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares - equal to a 4.1 percent stake - at $4.95 each.

  • Business Wire4 months ago

    Bristol-Myers Squibb and Compugen Announce Clinical Collaboration to Evaluate Therapeutic Regimen in Advanced Solid Tumors

    Bristol-Myers Squibb Company and Compugen today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo , in patients with advanced solid tumors.

  • PR Newswire5 months ago

    Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial

    HOLON, Israel, Sept. 20, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, was informed that Bayer AG dosed the first patient in the Phase 1 clinical trial of BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein, in patients with advanced solid tumors.  Under the terms of the collaboration and license agreement, Compugen is entitled to a milestone payment of $7.8 million at first patient dosing.

  • Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?
    Simply Wall St.5 months ago

    Should You Have Compugen Ltd’s (NASDAQ:CGEN) In Your Portfolio?

    Anyone researching Compugen Ltd (NASDAQ:CGEN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there areRead More...

  • PR Newswire5 months ago

    Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

    HOLON, Israel, Sept. 7, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG. PVRIG is a novel immune checkpoint identified by Compugen using its computational discovery capabilities. "Dosing the first patient with COM701, a first-in-class drug opportunity targeting a novel immune checkpoint we identified with our computational predictive platform, is a landmark event for us.

  • PR Newswire6 months ago

    Compugen Announces Appointment of Dr. Jean-Pierre Bizzari to its Board of Directors

    HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the appointment of Jean-Pierre Bizzari, M.D., formerly Executive Vice President and Global Head of Oncology at Celgene Corporation, to its Board of Directors. "I am delighted to welcome Jean-Pierre to Compugen's Board," said Paul Sekhri, Chairman of the Board. "I am confident that his extensive experience in oncology drug development will prove invaluable to Compugen.

  • Associated Press7 months ago

    Compugen: 2Q Earnings Snapshot

    The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...

  • PR Newswire7 months ago

    Compugen Reports Second Quarter 2018 Results

    Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...

  • ACCESSWIRE7 months ago

    Compugen Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. To listen ...